Vertex Pharmaceuticals (VRTX) stock gains as England opts to reimburse its CRSPR (CRSP)-partnered gene therapy Casgevy to ...

Charity organisation Sickle Cell Society has described the recommendation as a “major breakthrough” for sickle cell patients.

On CRSP's fourth-quarter 2024 earnings call, investors' focus will likely be on the sales figure of Casgevy, its first marketed product.

The therapy involves taking stem cells out of a patient's bone marrow and editing a gene in the cells in a laboratory and ...

People in England with sickle cell will be able to get the world’s first CRISPR-based medicine under an agreement between the ...

H.C. Wainwright analyst Mitchell Kapoor initiated coverage of Crispr Therapeutics (CRSP) with a Buy rating and $65 price target The firm says ...

In 2018, CRISPR Therapeutics advanced the first-ever CRISPR/Cas9 gene-edited therapy into the clinic to investigate the treatment of sickle cell disease and transfusion ... with leading companies ...

London: Britain's National Health Service (NHS) will provide a cutting-edge gene therapy that aims to cure sickle ... The therapy from Vertex Pharmaceuticals and CRISPR Therapeutics will cost ...

One of the world’s most expensive medicines will be used to treat some patients with sickle cell disease in England using the ...